Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

You may be eligible if

• Histologically confirmed squamous cell, adenocarcinoma, or adenosquamous cell carcinoma of the uterine cervix, meeting 1 of the following stage criteria:
• * Stage IIB-IIIB lymph nodes
• * Stage IB-IIA disease with biopsy-proven pelvic node metastases and/or tumor size \>= 5 cm
• No positive para-aortic lymph nodes
• Zubrod performance status 0-2
• WBC \>= 3,000/mm\^3
• Absolute granulocyte count \>= 1,500/mm\^3
• Platelet count \>= 100,000/mm\^3
• INR \< 1.5
• Total bilirubin =\< 1.5 mg/dL
• Serum creatinine =\< 1.5 mg/dL
• AST and ALT =\< 2.5 times upper limit of normal (ULN)
• Serum calcium =\< 1.3 times ULN
• Hemoglobin \>= 10 g/dL (transfusion allowed)
• Urine protein:creatinine ratio ? 0.5 OR urine protein \< 1,000 mg by 24-hour urine collection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• None of the following illnesses or conditions:
• * Medical illness preventing the use of full-dose chemotherapy
• * Evidence of bleeding diathesis or coagulopathy
• * Prior medical or psychiatric illness that would prevent informed consent or limit survival to \< 6 months
• * History of aneurysms, cerebrovascular accident, or arteriovenous malformations
• * Active gastrointestinal (GI) ulcers, GI bleeding, or active inflammatory bowel disease
• * Serious, nonhealing wound, ulcer, or current healing fracture
• * History of any type of fistula or GI perforation
• * Intra-abdominal abscess within the past 6 months
• No prior invasive malignancy (except nonmelanomatous skin cancer) unless disease free for \>= 3 years
• No significant traumatic injury within the past 28 days
• No clinically significant cardiovascular disease, such as the following:
• * Uncontrolled hypertension (blood pressure \> 160/90 mm Hg on medication)
• * Myocardial infarction within the past 12 months
• * Unstable angina within the past 12 months
• * New York Heart Association class II-IV congestive heart failure
• * Unstable symptomatic arrhythmia requiring medication (i.e., chronic atrial arrhythmia, atrial fibrillation, or paroxysmal supraventricular tachycardia)
• * Arterial thromboembolic events, including transient ischemic attack or clinically significant peripheral artery disease, within the past 6 months
• Arterial thromboembolic events, including transient ischemic attack or clinically significant peripheral artery disease, within the past 6 months
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
• No known HIV
• No prior organ transplant
• No prior surgery for carcinoma of the cervix other than biopsy
• No prior surgical debulking of pelvic or para-aortic nodes
• No prior pelvic radiotherapy, including transvaginal irradiation to control bleeding
• No prior systemic chemotherapy
• No major surgical procedure or open biopsy within the past 28 days or anticipation of need for major surgical procedure during the course of the study
• No fine needle aspirations or core biopsies within the past 7 days
• No concurrent major surgical procedure
• No concurrent epoetin alfa or Hypericum perforatum (St. John's wort)
• No concurrent intensity-modulated radiotherapy
• No concurrent transvaginal irradiation to control bleeding